CONTOUR Australia: Condition of Submental Fullness and Treatment

Study identification

• EU PAS number:
  EUPAS22012
• Study ID:
  36552
• Official title and acronym:
  CONTOUR Australia: Condition of Submental Fullness and Treatment
• DARWIN EU® study:
  No
• Study countries:
  Australia
• Study description:
  The primary objective of this registry is to develop a comprehensive understanding of how Belkyra is utilized in clinical practice in Australia, following its approval for the treatment of submental fullness due to submental fat, in order to further inform assessment of the risks and benefits associated with its treatment.
• Study status:
  Finalised

Research institutions and networks

Institutions

Parexel International

United States

Multiple centres: 6 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 16/10/2017

Actual: 16/10/2017

Study start date

Planned: 01/03/2018

Actual: 20/03/2018

Date of final study report

Planned: 29/05/2020

Actual: 12/03/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Allergan

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Non-EU RMP only

Other study registration identification numbers and links

CMO-AP-FAS-0505